Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:33 am EST
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 2,496.64 million compared to KRW 4,599.13 million a year ago. Net income was KRW 541.88 million compared to KRW 2,427.93 million a year ago. Basic earnings per share from continuing operations was KRW 20 compared to KRW 89 a year ago. Basic earnings per share was KRW 20 compared to KRW 89 a year ago.
For the nine months, sales was KRW 7,770.27 million compared to KRW 11,234.58 million a year ago. Net loss was KRW 868.22 million compared to net income of KRW 4,469.13 million a year ago. Basic loss per share from continuing operations was KRW 32 compared to basic earnings per share from continuing operations of KRW 164 a year ago. Basic loss per share was KRW 32 compared to basic earnings per share of KRW 164 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 
